BioDelivery Sciences International traded at $5.60 this Tuesday March 22nd, decreasing $0 or 0 percent since the previous trading session. Looking back, over the last four weeks, BioDelivery Sciences International lost 0.81 percent. Over the last 12 months, its price rose by 52.45 percent. Looking ahead, we forecast BioDelivery Sciences International to be priced at 5.44 by the end of this quarter and at 5.02 in one year, according to Trading Economics global macro models projections and analysts expectations.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website

BioDelivery Sciences International
BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company focuses on delivering therapies for individuals living with serious and debilitating chronic conditions. The Compnay builts a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA), drug-delivery technology to develop and commercialize new applications of therapies aimed at addressing important unmet medical needs. BEMA drug delivery technology consists of a small, bi-layered erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company's product candidates includes BELBUCA (buprenorphine buccal film), CIII, for Chronic Pain; Symproic (naldemedine), for Opioid Induced Constipation and ONSOLIS (fentanyl buccal soluble film) for Breakthrough Cancer Pain.